Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The myocardial ischemia market targets one situation where the blood flow to the heart is restricted leading to shortage of oxygen. This becomes a market with diagnostic tools, treatments, and continuing research to help address the intricacies of the myocardial ischemia.
The global burden myocardial ischemia is shared. It is definitely seen that various factors like hypertension, diabetes and lifestyles are building risks causing ischemic heart disease and as a result the changes in dynamics of market are hugely affected.
Myocardial ischemia market is reliant on diagnostics innovations. Simple non-invasive tests of assessment of pathogenetic changes and stimulation to acquire the necessary information in timely manner, are represented by electrocardiography (ECG); stress testing; as well as advanced imaging modalities, like cardiac MRI and CT angiography.
Diagnosis of myocardial ischemia is greatly dependant on the presence of biomarkers such as troponins and CK-MB. The continued research to identify new Biomarkers offering better diagnostic accuracy with some prognostic benefit drives the market.
Being a part of the pharmacological market segment, medications that help in managing myocardial ischemia are highlighted. Symptomatic relief as well as decrease in ischemia, and better maintenance of general heart health are achieved through the administration of antiplatelet agents, beta blockers, nitrates, and statins.
Myocardial ischemia market includes interventional cardiology procedures such as angioplasty and stent placement which are very significant part of the market. By unclogging the arteries, these interventions return badly needed high-pressure flow to the heart muscle, relieving ischemic symptoms and preventing further cardiac damage.
In cases of severe symptoms of myocardial ischemia, coronary artery bypass grafting (CABG) is an invasive option. New technologies in surgical techniques such as minimally invasive surgeries also drive the market owing to higher patient outcome and faster recovery times.
The technological fundamental driven are reflected by the progress in implantable devices, such as defibrillators and remote monitoring systems; which are indicative of the market forces. These improved aspects help in implementing proper management and also provides personalized care to patients with myocardial ischemia.
Market forces encompass patient education pertaining to lifestyle changes and risk factor management. Lifestyle modification with dietary alterations, exercise and smoking cessation take a central role in the comprehensive myocardial ischemia management approach.
In the myocardial ischemia market, telemedicine and remote monitoring solutions are growing in importance. These technologies ensure tracking of patients throughout, diagnose ischemic events at an early stage and aid interventions.
The cooperation between the pharmaceutical companies, the research institution and the health care facilities is basically important in establishing treatment options for myocardial ischemia. Continued clinical trials aim to develop novel therapies and optimize current treatment regimens.
The problems facing the myocardial ischemia market are such as how individual patients answer to treatment, personalized medication and burden it is to be treated by the cardiovascular diseases. The outlook for the future involves responses to such challenges using precision medicine, research continuation, and the adoption of the everybody’s health is everybody’s responsibility’ approach to cardiovascular health.
Myocardial Ischemia Market Highlights:
Myocardial Ischemia Market Overview
The Myocardial Ischemia Market is expected to reach USD 1186.12 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030 Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.
Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.
Market Dynamics
Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased. This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.
Myocardial Ischemia Market Size, by End User, 2017 (USD Million)  
 Source: MRFR Analysis
Segmentation
The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic. Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test. The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.
Key Players
The prominent players in the myocardial ischemia market are Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).
Some of the key strategies followed by the players operating in the myocardial ischemia market were innovation, product development, acquisition, and expansion.
Asia-Pacific Myocardial Ischemia Market Share, by Country, 2017 (%) 
Source: MRFR Analysis
Regional Analysis
The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the brain ischemia ischemiamarket during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population. The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).
Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.
Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.
Key Updates
- In July 2016, Angionetics Inc., a subsidiary of Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a USD 3,000,000 investment, to support the Generx Phase 3 clinical and commercialization development program.
- In February 2018, Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.
- In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).
Market Segmentation
Myocardial Ischemia Market, by Type
- Symptomatic
- Asymptomatic
Myocardial Ischemia Market, by Treatment & Diagnosis
- Diagnosis
- Treatment
Myocardial Ischemia Market, by End User
- Hospitals & Clinics
- Diagnostic Centres
- Ambulatory Surgery Centres
Myocardial Ischemia Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Republic of Korea
- Rest of Asia-Pacific
- Middle East & Africa
- United Arab Emirates
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of The Middle East & Africa
Available Additional Customizations
- Regulatory scenario
Intended Audience
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
- Pharmaceutical companies
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
